Table 1.
Patient baseline characteristics
| All (n = 89) | Regorafenib (n = 58) | ICI (n = 31) | p-value | |
|---|---|---|---|---|
| Age (years), median (IQR) | 63.0 (58.0, 68.0) | 63.5 (59.0, 71.5) | 61.0 (54.5, 66.5) | 0.10 |
| Sex/male, n (%) | 72 (80.9) | 48 (82.8) | 24 (77.4) | 0.74 |
| BCLC stage, n (%) | 0.24 | |||
| B | 15 (16.9) | 12 (20.7) | 3 (9.7) | |
| C | 74 (83.1) | 46 (79.3) | 28 (90.3) | |
| MVI, n (%) | 46 (51.7) | 25 (43.1) | 21 (67.7) | 0.05 |
| VP stage, n (%) | 0.12 | |||
| VP2 | 5 (10.9) | 3 (12.0) | 2 (9.5) | |
| VP3 | 30 (65.2) | 19 (76.0) | 11 (52.4) | |
| VP4 | 11 (23.9) | 3 (12.0) | 8 (38.1) | |
| Out of up-to-7 criteria, n (%) | 50 (56.2) | 29 (50.0) | 21 (67.7) | 0.17 |
| Out of up-to-11 criteria, n (%) | 39 (43.8) | 20 (34.5) | 19 (61.3) | 0.03* |
| EHM, n (%) | 53 (59.6) | 34 (58.6) | 19 (61.3) | 0.99 |
| Previous TACE, n (%) | 68 (76.4) | 45 (77.6) | 23 (74.2) | 0.92 |
| Previous RFA, n (%) | 25 (28.1) | 18 (31.0) | 7 (22.6) | 0.55 |
| HBV history (%), n (%) | 51 (57.3) | 30 (51.7) | 21 (67.7) | 0.22 |
| HCV history (%), n (%) | 25 (28.1) | 18 (31.0) | 7 (22.6) | 0.55 |
| Cirrhosis, n (%) | 74 (83.1) | 47 (81.0) | 27 (87.1) | 0.67 |
| Baseline NLR, median (IQR) | 3.9 (2.7, 6.3) | 3.77 (2.0, 6.3) | 4.1 (3.1, 6.2) | 0.46 |
| Baseline platelets (103/µL), median (IQR) | 127.0 (92.0, 184.5) | 119.5 (87.5, 163.5) | 143.0 (96.0, 216.0) | 0.33 |
| Baseline AST (U/L), median (IQR) | 54.0 (40.0, 80.0) | 52.0 (39.0, 72.5) | 69.5 (44.5, 87.0) | 0.17 |
| Baseline ALT (U/L), median (IQR) | 41.0 (30.0, 62.0) | 37.0 (30.8, 55.3) | 48.0 (29.5, 73.0) | 0.27 |
| Baseline albumin (g/dL), median (IQR) | 3.8 (3.4, 4.1) | 3.9 (3.5, 4.1) | 3.7 (3.4, 4.1) | 0.70 |
| Baseline AFP (ng/mL), median (IQR) | 280.6 (17.8, 2079.2) | 183.9 (12.3, 1920.8) | 468.0 (146.3, 2162.6) | 0.13 |
| Baseline ALBI II+III, n (%) | 49 (56.3) | 31 (54.4) | 18 (60.0) | 0.78 |
| Baseline APRI, median (IQR) | 1.49 (0.9, 2.0) | 1.5 (1.0, 2.0) | 1.4 (0.9, 1.9) | 0.90 |
| Baseline FIB-4, median (IQR) | 4.47 (2.60, 6.28) | 4.6 (2.7, 6.8) | 4.1 (2.5, 6.0) | 0.31 |
| Combine LRTa, n (%) | 19 (21.3) | 14 (24.1) | 5 (16.1) | 0.54 |
| Combine other systemic treatment, n (%) | 3 (3.4) | 2 (3.4) | 1 (3.2) | 1.00 |
ICI, immune checkpoint inhibitor; BCLC, Barcelona Clinic Liver Cancer classification; MVI, microvascular invasion; VP, portal vein invasion; EHM, extra-hepatic metastasis; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; HBV, hepatitis B virus; HCV, hepatitis C virus; NLR, neutrophil-to-lymphocyte ratio; AST, aspartate aminotransferase; ALT, alanine transaminase; AFP, alpha fetoprotein; ALBI grade, albumin-bilirubin grade; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4 index; LRT, locoregional treatment; IQR, interquartile range.
a
Transarterial chemoembolization or radiofrequency ablation.
*
P < 0.05.